evipedia.ai
← Back

Sarcosine for Health & Longevity

Evidence Review created on 08/14/2026 using AI4L / Opus 5

Also known as: N-methylglycine, Monomethylglycine, Methylglycine, Sarcosin

Motivation

Sarcosine (N-methylglycine) is a small amino acid that the body makes from glycine and that also turns up in muscle, egg yolk, and legumes. Sold as an inexpensive powder, it is best known for strengthening one of the brain’s main signaling systems by slowing the removal of glycine from the space between nerve cells.

Chemists isolated it from muscle tissue in the nineteenth century, and for more than a hundred years it was treated as an unremarkable waypoint in the body’s handling of methyl groups. Two separate lines of work revived interest: psychiatric researchers began adding it to standard medication for serious mental illness, and aging researchers noticed that its level in blood falls as people grow older and rises when food is restricted.

This review examines sarcosine as a health and longevity intervention: how it works in the body, which benefits and harms have been recorded, how it has been dosed and monitored, and how strong or weak the evidence behind each of those points currently is.

Benefits - Risks - Protocol - Conclusion

High-level sources that give substantial depth on sarcosine itself or on the transporter and receptor machinery through which it acts.

No content from the priority experts and platforms could be found: neither web searches nor an on-site search of lifespan.io returned any article, episode, or lecture from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension, or Lifespan.io that discusses sarcosine. Five qualifying sources were nonetheless identified, so the list is not padded.

Grokipedia

  • Sarcosine

    Covers chemical properties, biosynthesis and metabolism, production methods, industrial uses, medical and research significance, and historical development — useful for the non-clinical, industrial side of the compound.

Examine

  • Sarcosine

    Grades the schizophrenia evidence from four trials in 183 participants, gives a body-weight-scaled dose, and flags the unresolved question of whether sarcosine acts as a co-carcinogen.

ConsumerLab

No ConsumerLab article, product review, or independent test report exists for sarcosine; the site has never included it in a testing program.

Systematic Reviews

Pooled analyses of the randomized evidence, which is concentrated almost entirely in schizophrenia augmentation.

Sarcosine’s principal trade-off is between symptomatic benefit and the prostate-cancer biology attached to the same molecule. The benefit side is represented above by five pooled analyses; the risk side is unrepresented, because no systematic review or meta-analysis of sarcosine and prostate cancer risk has been published — that literature consists of individual cohort and case-control studies, cited in the Potential Risks & Side Effects section.

Mechanism of Action

Sarcosine is N-methylglycine. It is formed when glycine N-methyltransferase (GNMT, the liver enzyme that disposes of surplus methyl groups) moves a methyl group from S-adenosylmethionine (SAM, the body’s universal methyl donor) onto glycine. It is cleared by sarcosine dehydrogenase (SARDH), which converts it back to glycine and releases a one-carbon unit into folate metabolism, the pathway supplying carbon fragments for building DNA.

Its central action is blockade of glycine transporter type 1 (GlyT1, the pump that clears glycine out of the synapse). Blocking that pump raises glycine between nerve cells and increases signaling through the N-methyl-D-aspartate (NMDA) receptor, the glutamate receptor governing learning and the strengthening of connections between nerve cells, which needs glycine as a co-agonist (a second molecule required alongside the main signal). A competing mechanistic account exists: sarcosine also binds the receptor’s glycine site directly and produces less desensitization than glycine, so part of the effect may not be transport-mediated at all (Zhang et al., 2009).

A separate, non-neural mechanism is proposed for aging: sarcosine induces autophagy (the cell’s disposal of damaged components) in cultured cells and mice (Walters et al., 2018).

Pharmacologically, oral sarcosine shows linear kinetics, peaks at roughly 1.5–2.5 hours, and has a half-life near one hour. It is not selective for a single target, distributes to muscle and kidney, and is eliminated by SARDH-mediated breakdown and renal excretion.

Historical Context & Evolution

Sarcosine was isolated in 1847 by Justus von Liebig from the breakdown of creatine taken from muscle, which is why it carries the Greek root for flesh. Its original standing was not therapeutic: it was a metabolic intermediate, later joined by two industrial roles that still dominate global production — sarcosinate detergents used in toothpaste and shampoo, and sarcosine oxidase used as the reagent enzyme in laboratory creatinine assays.

Sarcosinemia (the inherited condition of lifelong raised sarcosine) was picked up by newborn metabolic screening programs from the 1960s onward. Screening found affected individuals who were clinically normal, and although occasional neurodevelopmental abnormalities were reported, the condition is generally regarded as benign — evidence that lifelong elevation is tolerated (Deutsch et al., 2006).

Therapeutic interest began with the glutamate hypothesis of schizophrenia. A 2004 placebo-controlled trial added 2 g daily to existing antipsychotics and reported improvement in positive, cognitive, and negative symptoms (blunted affect, sparse speech, withdrawal) (Tsai et al., 2004). Pharmaceutical companies pursued the same target with selective molecules; the most advanced, bitopertin, missed its primary endpoints in phase III trials for negative symptoms (Bugarski-Kirola et al., 2017).

Two later findings redirected attention. In 2009 a metabolomic screen named sarcosine as a marker of prostate cancer progression (Sreekumar et al., 2009), and in 2018 a separate screen found it falling with age and rising under dietary restriction. Neither line is settled; the first has been contradicted by prospective cohorts, and the second has never been tested in humans.

Expected Benefits

High 🟩 🟩 🟩

Reduction of Negative and Overall Symptoms in Schizophrenia

Added at 2 g daily to an existing antipsychotic other than clozapine, sarcosine reduces total symptom burden and, most consistently, negative symptoms — blunted affect, poverty of speech, withdrawal. Seven double-blind randomized controlled trials (RCTs) and four independent pooled analyses agree on direction. Effects are largest in chronic, clinically stable, non-treatment-resistant patients and absent in clozapine-treated patients. This is not a longevity endpoint, but it is the only place where the evidence reaches this grade (Chang et al., 2020; Lane et al., 2005).

Magnitude: Standardized mean difference (SMD, the effect size expressed in standard-deviation units) of 0.51 for overall symptoms, 95% confidence interval (CI, the range consistent with the data) 0.26–0.76, across seven trials in 326 participants; negative symptoms SMD −0.65 (95% CI −1.10 to −0.19) in a separate network analysis.

Medium 🟩 🟩

Augmentation of Antidepressant Response in Major Depression

Two randomized trials support an antidepressant effect. In the first, sarcosine 500–1,500 mg daily outperformed citalopram as monotherapy on depression ratings, global function, and remission rate. In the second, 1 g daily added to a serotonin reuptake inhibitor beat placebo augmentation and raised serum brain-derived neurotrophic factor (BDNF, a growth factor supporting nerve-cell survival). Both trials are small, single-centre, and eight weeks or shorter, so the estimate is unstable (Huang et al., 2013; Padhan et al., 2024).

Magnitude: An additional 4.6-point fall (95% CI 1.7–7.5) on the Montgomery-Åsberg Depression Rating Scale (MADRS, a clinician-rated depression scale) over eight weeks compared with antidepressant plus placebo, with significantly higher response and remission rates.

Low 🟩

Reduction of Obsessive-Compulsive Symptoms

A ten-week open-label trial in 25 outpatients, using the same receptor mechanism, produced a modest fall in symptom scores, clearest in medication-naive participants, with onset within four weeks. There is no placebo control, so expectancy cannot be separated from drug effect (Wu et al., 2011).

Magnitude: Mean 19.8% ± 21.7% reduction in Yale-Brown Obsessive Compulsive Scale (Y-BOCS, the standard symptom rating scale) score; 8 of 25 participants exceeded a 35% reduction.

Improvement in Cognitive Performance ⚠️ Conflicted

Evidence points both ways. The sarcosine-only pooled analysis found no significant cognitive benefit, and a 12-week trial found none for sarcosine alone. Both found a large benefit when sodium benzoate was added. No trial has tested cognition in healthy adults (Chang et al., 2020; Lin et al., 2017).

Magnitude: Sarcosine alone SMD 0.27 (95% CI −0.06 to 0.60, not significant); sarcosine 2 g plus sodium benzoate 1 g SMD 1.08 (95% CI 0.45–1.71) for global cognitive function.

Relief of Neuropsychiatric Symptoms in Parkinson’s Disease with Dementia

An eight-week placebo-controlled trial in 30 patients found improvement in depression and neuropsychiatric ratings at weeks two and four, largest in mild-to-moderate disease, without worsening movement or cognition. Benefit faded by week eight, suggesting the effect is temporary (Tsai et al., 2014).

Magnitude: Separation from placebo on depression ratings at week two (p = 0.049) and neuropsychiatric ratings at week four (p = 0.039); the trial reports no between-group effect size.

Speculative 🟨

Autophagy Induction as a Dietary-Restriction Mimic

Sarcosine falls with age, rises with dietary restriction, is elevated in long-lived dwarf mice, and increases autophagic flux. The basis is mechanistic and preclinical only, with no human outcome data (Walters et al., 2018).

Preservation of Muscle Mass in Sarcopenia

Plasma sarcosine falls with sarcopenia (age-related muscle loss) in two human cohorts, and in mice it enhances muscle regeneration. The basis is observational and preclinical, with no supplementation trial (Liu et al., 2025).

Benefit-Modifying Factors

  • Concurrent clozapine use: The single strongest modifier. Every trial and pooled analysis that separated clozapine-treated patients found the symptom benefit abolished, probably because clozapine already potentiates the same receptor.

  • Illness chronicity and stability: Benefit is concentrated in chronic, clinically stable presentations; pooled analysis found the effect confined to trials in stable patients, so timing of use changes the expected return (Chang et al., 2020).

  • Genetic variation in sarcosine handling: Reduced-function variants in sarcosine dehydrogenase slow clearance and raise circulating levels for a given dose, while glycine N-methyltransferase variants alter endogenous production; neither has been tested prospectively as a response predictor.

  • Baseline biomarker levels: Lower baseline serum glycine and lower baseline sarcosine plausibly leave more room for the intervention to move the system, and trial data show serum glycine rising with treatment; no threshold predicting response has been validated.

  • Sex: Pooled analysis found effect sizes rising with the proportion of women enrolled, though not significantly (Chang et al., 2020). Trials were male-predominant, so estimates in women rest on fewer participants.

  • Age: All benefit data come from adults aged roughly 18–65. Endogenous sarcosine declines with age, which is the rationale for use in older adults, but the oldest end of the target range is untested.

  • Pre-existing health conditions: Renal impairment slows elimination; a history of prostate disease shifts the risk-benefit balance rather than the benefit itself; nothing suggests reduced efficacy in metabolic disease.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild, Transient Adverse Effects

Across the randomized trials, sarcosine at 1–4 g daily produced no adverse-event signal distinguishable from placebo. Reported events were mild and transient — headache, nausea, and, less often, sleep disturbance. A dedicated six-month randomized trial found no change in cardiometabolic markers or body composition. Follow-up beyond six months has never been collected, so this profile describes short-term use only (Goh et al., 2021; Strzelecki et al., 2015).

Magnitude: Dropout for any cause and dropout for adverse events did not differ from placebo in pooled analyses; in a ten-week trial 1 of 25 participants withdrew, for transient headache.

Medium 🟥 🟥

Promotion of Prostate Cancer Invasion ⚠️ Conflicted

Sarcosine added to benign prostate cells makes them behave like invasive cancer cells, and prostate tumors show increased sarcosine-producing and reduced sarcosine-clearing enzymes. Human epidemiology contradicts itself: one large prospective screening cohort found rising risk with rising serum sarcosine, while a larger Norwegian cohort found the opposite direction. No study has tested supplemental sarcosine, so the exposure that matters remains unmeasured (Khan et al., 2013; Koutros et al., 2013; de Vogel et al., 2014).

Magnitude: Highest versus lowest quartile of serum sarcosine gave an odds ratio (OR, the ratio of the odds of disease between groups) of 1.30 (95% CI 1.02–1.65) in one cohort; the highest versus lowest quintile gave 0.86 (95% CI 0.72–1.01) — the opposite direction — in another.

Low 🟥

Excitatory Overstimulation

Sarcosine increases signaling at the receptor mediating excitotoxic injury and desensitizes it less than glycine, producing larger calcium influx in neurons. Cell-death measures were nonetheless unchanged. The rare neurodevelopmental abnormalities seen in inherited sarcosine elevation are attributed to this pathway (Zhang et al., 2009; Deutsch et al., 2006).

Magnitude: Direction is toward greater calcium entry per receptor activation, and it holds where receptors are already primed by other stressors; the literature reports no clinical outcome figure in supplemented adults.

Interference with Laboratory Assays

Supplementation raises circulating and urinary sarcosine, the analyte used in experimental prostate-cancer metabolite panels and the reagent substrate in most enzymatic creatinine assays. Results from either can therefore be misread while supplementation continues (Amiaz et al., 2015; Khan et al., 2013).

Magnitude: Not quantified in available studies. No study has measured assay bias in supplemented humans; the concern rests on assay chemistry and on pharmacokinetic data showing dose-proportional rises in serum sarcosine.

Speculative 🟨

Perturbation of One-Carbon and Methyl-Group Balance

Sarcosine sits between the methyl donor pool and folate metabolism, so sustained intake could shift methyl-group availability. No human study has measured methylation markers, homocysteine, or folate status during supplementation.

Risk-Modifying Factors

  • Male sex and prostate status: The prostate-cancer concern applies only to men, and disproportionately to those with existing prostate disease, a rising prostate marker, or a family history.

  • Age: Prostate cancer prevalence rises steeply after 50, so the same uncertain relative signal carries a larger absolute stake in older men. Older adults also have lower baseline renal clearance.

  • Genetic variation: Sarcosine dehydrogenase deficiency causes lifelong elevation and is usually benign, but reduced-function carriers will accumulate more from a given dose. Glycine N-methyltransferase deficiency additionally raises liver enzymes.

  • Baseline biomarker levels: A raised prostate-specific antigen, an abnormal free-fraction ratio, or elevated liver enzymes before starting all change how a subsequent change should be read.

  • Pre-existing health conditions: Kidney impairment slows elimination; seizure disorders and recent stroke matter because the pathway increases excitatory signaling; clozapine treatment removes the benefit while leaving the risks.

Key Interactions & Contraindications

  • Clozapine (absolute efficacy interaction, caution): Adding sarcosine to clozapine produced no improvement over clozapine alone in a dedicated randomized trial and in every pooled subgroup analysis. Consequence: exposure without benefit (Lane et al., 2006).

  • NMDA receptor antagonists (caution, mechanistic opposition): Memantine, ketamine, and esketamine act against sarcosine at the same receptor. Consequence: mutual blunting of the intended effect. Mitigation: these agents are not combined for the same indication.

  • Other antipsychotics (monitor, potentiating): Risperidone, olanzapine, and first-generation agents show additive symptom benefit with sarcosine. Consequence: greater improvement, and any dose change should be made one variable at a time.

  • Sodium benzoate (monitor, additive): This inhibitor of D-amino acid oxidase (the enzyme that clears D-serine) and sarcosine raise receptor activity by complementary routes, giving the largest cognitive signal. Consequence: amplified effect, tested at 1 g plus 2 g daily.

  • Glycine and D-serine supplements (monitor, additive): All three raise activity at the same receptor site. Consequence: unpredictable additive stimulation. Mitigation: one agent at a time rather than stacking.

  • Over-the-counter dextromethorphan (caution, opposition): Cough preparations containing dextromethorphan block the same receptor. Consequence: temporary loss of the intended effect during a course of cough medicine.

  • Over-the-counter magnesium (monitor, opposition): Magnesium blocks the receptor channel pore at physiological levels. Consequence: theoretical blunting only; no clinical interaction has been reported, and separation of dosing is not established as necessary.

  • Other interventions (monitor): Prolonged fasting and calorie restriction raise endogenous sarcosine, so supplementation during a restriction protocol adds to an already elevated level.

Populations who should avoid Sarcosine:

  • Men with active, untreated, or biochemically recurrent prostate cancer, or with a confirmed prostate-specific antigen rise above 4.0 ng/mL pending workup
  • People taking clozapine, in whom no benefit has been demonstrated
  • Pregnancy and lactation, for which no safety data of any kind exist
  • Severe renal impairment (estimated glomerular filtration rate below 30 mL/min/1.73 m²), where clearance of sarcosine and glycine is reduced
  • Active seizure disorder or stroke within 90 days, given increased excitatory signaling
  • Children and adolescents outside a supervised trial setting

Risk Mitigation Strategies

  • Baseline prostate assessment in men: Protocols measure total prostate-specific antigen, and the free fraction if total is 4–10 ng/mL, before the first dose. This establishes the reference point against which any later rise attributed to sarcosine can be judged.

  • Prostate re-check at six months: The same marker is repeated at 6 months and then every 6–12 months. This limits the window during which an unnoticed rise could progress while the prostate-cancer-promotion signal remains unresolved.

  • Titration from 500 mg daily: A schedule of 500 mg for one week, then 1 g, reaching 2 g by week three. This surfaces headache, nausea, or sleep disturbance at the lowest exposure producing them.

  • Cap at 2 g daily: Exposure stays at the 2 g dose used in the controlled trials. Doses of 4 g have only open-label safety data in 17 people, so higher intakes leave the evidence base entirely.

  • Dosing before 16:00: The final dose falls no later than mid-afternoon. Given the excitatory mechanism, this reduces the chance of delayed sleep onset in sensitive individuals.

  • Declared use before laboratory testing: Supplementation is noted on the requisition for creatinine, kidney function, and any metabolite panel. This prevents misreading of assays whose chemistry uses sarcosine as substrate or analyte.

  • No stacking of receptor-site agents: Sarcosine is kept apart from glycine, D-serine, and D-cycloserine. This prevents additive stimulation at a receptor whose overactivation is the mechanism behind the excitotoxicity concern.

Therapeutic Protocol

  • Standard dose: 2 g daily is the dose used in almost every controlled trial and the reference protocol. Examine expresses the same target as roughly 30 mg per kilogram of body weight.

  • Originating protocol: The 2 g add-on schedule was established by Guochuan Tsai and Hsien-Yuan Lane at China Medical University Hospital in Taiwan, whose group ran most of the sarcosine trials.

  • Competing approach — dual receptor enhancement: The same group’s alternative combines sarcosine 2 g with sodium benzoate 1 g daily, targeting two enzymes at once; it produced the largest cognitive effect recorded.

  • Competing approach — monotherapy: Trials in drug-naive patients and in depression used sarcosine alone at 500–2,000 mg daily, without a background agent, and reported benefit in that setting.

  • Split versus single dose: The half-life near one hour argues for splitting 2 g into two 1 g doses. All published trials nonetheless used once-daily dosing, so the split schedule is inference, not tested practice.

  • Time of day: Morning dosing is standard in the trials. The excitatory mechanism argues against evening administration; no trial has compared timing directly.

  • Half-life: Roughly one hour, with peak plasma levels at 1.5–2.5 hours and linear kinetics from 2 g to 4 g daily (Amiaz et al., 2015).

  • Genetic polymorphisms: Sarcosine dehydrogenase and glycine N-methyltransferase variants alter clearance and endogenous production, so carriers reach different levels on the same dose. Neither has been used prospectively to set a dose.

  • Sex differences: Pooled analysis found larger effects as the enrolled proportion of women rose (Chang et al., 2020). No sex-specific dose has been proposed, and pharmacokinetic data in women are sparse.

  • Age: Trials enrolled adults up to about 65. Older adults have lower renal clearance and lower baseline sarcosine, which argues for the lower end of the range and slower titration.

  • Baseline biomarkers: Lower baseline serum glycine leaves more headroom for the intervention. Serum glycine rises measurably on treatment and is the only marker shown to track dosing.

  • Pre-existing conditions: Clozapine treatment removes the response; renal impairment raises exposure; prostate disease changes the balance rather than the dose. Chronic stable illness responds better than acute exacerbation.

Discontinuation & Cycling

  • Intended duration: Trials ran 6 weeks to 6 months. No study has tested lifelong use, so the intervention has only been validated as a defined course rather than as a permanent addition.

  • Withdrawal effects: None reported in any trial. Sarcosine is an endogenous metabolite cleared within hours, and its inherited elevation resolves without a withdrawal syndrome.

  • Loss of effect on stopping: Benefit appears to depend on continued exposure. In the Parkinson’s disease trial, separation from placebo faded while treatment continued, suggesting adaptation rather than persistence.

  • Tapering: Not applicable. The short half-life and absence of receptor downregulation data mean abrupt cessation has been used throughout the trial literature without incident.

  • Cycling: Never studied. The observed fading of effect provides a theoretical rationale for periodic breaks, but no schedule has been tested and none can be derived from the evidence.

Sourcing and Quality

  • Form to buy: Free-base sarcosine powder or capsules, labelled as N-methylglycine, with a stated purity of at least 98%. It is a single small molecule with no salt forms, isomers, or standardized extracts to compare.

  • Critical labelling trap: Sodium lauroyl sarcosinate and cocoyl sarcosinate are detergents used in toothpaste and shampoo, not the amino acid. Any product whose name ends in “sarcosinate” is a surfactant and is not ingestible.

  • Third-party testing: The marker of quality is a batch-specific certificate of analysis from an independent laboratory showing identity by chromatography, purity, and screens for heavy metals and microbial contamination — not a vendor’s own in-house statement.

  • Reputable suppliers: Nootropics Depot and LiftMode both sell sarcosine and publish batch analytical testing for it, which is the practical differentiator in a category dominated by unlabelled bulk powder.

  • Pharmaceutical grade is unnecessary: No compounding pharmacy formulation exists, and none is needed; the trials used ordinary food-grade sarcosine at 2 g daily.

Practical Considerations

  • Time to effect: Symptom change appeared at week 1 in one open-label study, week 2 in most randomized trials, and by week 4 in obsessive-compulsive symptoms. Trials measuring cognition ran 12 weeks before separation appeared.

  • Pitfall — expecting benefit alongside clozapine: The most reliable negative finding in the literature. Anyone taking clozapine who adds sarcosine is buying exposure with no demonstrated return.

  • Pitfall — buying the wrong molecule: Confusing sarcosine with sarcosinate surfactants, which dominate search results because they are far larger industrial products.

  • Pitfall — stopping too early: Discontinuing before week 4. Most trials show no separation from control at the two-week visit.

  • Regulatory status: Sarcosine is sold in the United States as a dietary supplement and is not an approved medicine in any major market; all human use for the effects described here is outside any licensed indication.

  • Cost and accessibility: Inexpensive and unrestricted — bulk powder runs well under one US dollar per day at 2 g. Neither cost nor access is a limiting factor.

Interaction with Foundational Habits

  • Sleep: Direction is a potential blunting of sleep onset, by the excitatory receptor mechanism. No trial measured sleep as an endpoint and no sleep-laboratory recordings exist. Practical consequence: take the final dose before mid-afternoon, and treat evening dosing as untested rather than merely inadvisable.

  • Nutrition: Direction is direct and additive. Meat, egg yolk, and legumes contribute small dietary amounts, and sarcosine breakdown depends on riboflavin-containing and folate-linked enzymes, so adequate riboflavin, folate, and vitamin B12 support its clearance. Caloric restriction and prolonged fasting raise endogenous levels, making supplementation partly redundant during a restriction protocol.

  • Exercise: No direct interaction has been demonstrated in either direction. Sarcosine is a creatine breakdown product but does not enter creatine synthesis, and nothing indicates it blunts or enhances the training response. No timing relative to workouts has any evidentiary basis.

  • Stress management: Direction is potentiating and indirect. In rodent chronic unpredictable stress models, sarcosine reversed the behavioural deficits, and human antidepressant trials point the same way. Practical consequence: any mood benefit is likely to overlap with, rather than replace, established stress-reduction practices.

Monitoring Protocol & Defining Success

Before the first dose, a baseline panel establishes the reference points that make later changes interpretable. For men this centres on prostate markers, because the compound’s most unresolved risk concerns the prostate; for everyone it includes kidney function, a liver enzyme, and homocysteine, since the compound is renally cleared and sits inside methyl-group metabolism. Where available, a research metabolite panel documents the starting sarcosine or glycine level. Ongoing testing follows a simple cadence: repeat the full panel at 3 months, again at 6 months, and thereafter every 6–12 months for as long as use continues, with prostate markers repeated on the same schedule. Because the compound’s effects appear within weeks and fade after stopping, subjective response is judged at 4 and 12 weeks rather than at the laboratory intervals.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
PSA, total Below 1.0 ng/mL under age 60; below 1.5 ng/mL from 60 Tracks the prostate signal that the cancer-biology data raise PSA is prostate-specific antigen, a protein released by the prostate. Conventional threshold is 4.0 ng/mL, far higher. Draw before digital examination, and avoid ejaculation or cycling for 48 hours. Confirm any rise on a repeat sample
Free PSA, percentage of total Above 25% Separates benign enlargement from cancer when total PSA rises Interpretable only when total PSA is 4–10 ng/mL. Run on the same draw as total PSA
eGFR Above 90 mL/min/1.73 m² Sarcosine and the glycine it yields are cleared by the kidney eGFR is the estimated glomerular filtration rate, a calculated score of how well the kidneys filter. Most laboratories derive it from creatinine measured with a sarcosine oxidase enzyme cascade, so declare supplement use. Fasting not required
ALT Below 25 U/L in men, below 20 U/L in women The enzyme producing sarcosine is liver-based; disturbance shows here first ALT is alanine aminotransferase, an enzyme released when liver cells are stressed. Conventional upper limits of 40–55 U/L are far more permissive. Fasting not required; best paired with aspartate aminotransferase
Homocysteine Below 9 µmol/L Reads the one-carbon pathway that sarcosine breakdown feeds Conventional range extends to 15 µmol/L. Fasting sample, separated promptly, best paired with folate and vitamin B12
Serum sarcosine or glycine No established target exists; track the change from the individual’s own baseline instead Confirms that oral dosing actually moves the metabolite Offered only through research or specialist metabolomic panels. Draw fasting in the morning before the day’s dose

Qualitative markers, tracked weekly against the pre-treatment baseline:

  • Sleep onset latency and any new difficulty falling asleep
  • Mental clarity and speed of processing during demanding tasks
  • Mood stability and motivation, using a consistent self-rating
  • Verbal fluency and social engagement, the domains where negative-symptom benefit appears
  • Headache, nausea, and any sense of overstimulation in the first three weeks

Emerging Research

  • Registry status: A ClinicalTrials.gov search on 14 August 2026 returned 12 registered sarcosine studies. Every one is completed or withdrawn; none is recruiting. No trial anywhere targets an aging, longevity, or healthy-adult cognition endpoint, which is the largest gap in the field.

  • Most recent completed trial: NCT04975100, a phase 4 randomized trial of add-on sarcosine in 60 patients with major depressive disorder, completed in 2023 and published in 2024. Its primary endpoint was change in depression rating over eight weeks.

  • PULSAR biomarker programme: NCT01503359, a 70-participant phase 2 trial in Poland, continues to yield biomarker analyses years after completion, most recently on the glial protein S100B (Pawlak et al., 2026).

  • Molecular imaging: NCT02462447 tested carbon-11-labelled sarcosine as a positron emission tomography tracer in 20 men, comprising a prostate cancer group and healthy volunteers. This line could resolve, or worsen, the prostate question by mapping where sarcosine accumulates.

  • Direction that could strengthen the case: Whether autophagy induction translates from cells and mice into humans. No trial has measured autophagic markers after oral sarcosine (Walters et al., 2018).

  • Direction that could weaken the case: Whether the prostate-invasion biology holds at supplemental doses. Two large prospective cohorts already disagree in direction (Koutros et al., 2013; de Vogel et al., 2014).

  • Combination strategy: Whether pairing sarcosine with sodium benzoate reproduces its cognitive advantage outside schizophrenia. The signal comes from one trial carried into a network analysis (Liang et al., 2025).

  • Pediatric behavioural signal: A 116-child randomized trial found benefit confined to oppositional symptoms in attention deficit hyperactivity disorder, an isolated finding awaiting replication (Tzang et al., 2016).

Conclusion

Sarcosine is a small, cheap, naturally occurring amino acid that raises activity at one of the brain’s principal excitatory receptors, and that also falls with age and rises with food restriction. Those two facts have produced two almost unconnected bodies of evidence.

The clinical body is real but narrow. Repeated randomized trials and several pooled analyses show that adding sarcosine to standard treatment reduces the withdrawal and flattening seen in long-standing psychosis, an effect that disappears entirely alongside one particular antipsychotic. Smaller randomized work points the same way in depression, and weaker, uncontrolled work in obsessive-compulsive symptoms and in Parkinson’s-related mood disturbance. Effects on thinking and memory remain genuinely disputed, and no trial has ever enrolled a healthy adult.

The longevity body is entirely preclinical. The recycling mechanism that makes sarcosine interesting to people optimizing for long-term health, and a newer signal around muscle preservation, have been shown only in cells, animals, and blood measurements.

Two cautions carry real weight for this audience. The same molecule promotes invasion in prostate cell and animal models, while the two large human studies that tracked people over time disagree about direction. And nothing beyond six months has been observed. Over short periods it causes few side effects, the cost of trying is trivial, and the quality of the underlying evidence — graded low to very low by its own reviewers, and produced largely by a single research group — is the limiting factor.

Top - Benefits - Risks - Protocol